Challenges in design and characterization of ligand-targeted drug delivery systems

被引:203
|
作者
Muro, Silvia [1 ,2 ]
机构
[1] Univ Maryland Coll Pk, Inst Biosci & Biotechnol Res, College Pk, MD 20742 USA
[2] Univ Maryland Coll Pk, Sch Engn, Fischell Dept Bioengn, College Pk, MD 20742 USA
基金
美国国家卫生研究院;
关键词
Drug delivery; Active targeting; Ligand; Cell surface binding; Internalization; Subcellular transport; ANGIOTENSIN-CONVERTING ENZYME; CELL-PENETRATING PEPTIDES; IN-VIVO; INTRACELLULAR DELIVERY; GENE DELIVERY; ENDOTHELIAL ICAM-1; TUMOR-GROWTH; ANTIBODY; PROTEIN; RECEPTOR;
D O I
10.1016/j.jconrel.2012.05.052
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Targeting of therapeutic agents to molecular markers expressed on the surface of cells requiring clinical intervention holds promise to improve specificity of delivery, enhancing therapeutic effects while decreasing potential damage to healthy tissues. Drug targeting to cellular receptors involved in endocytic transport facilitates intracellular delivery, a requirement for a number of therapeutic goals. However, after several decades of experimental design, there is still considerable controversy on the practical outcome of drug targeting strategies. The plethora of factors contributing to the relative efficacy of targeting makes the success of these approaches hardly predictable. Lack of fully specific targets, along with selection of targets with spatial and temporal expression well aligned to interventional requirements, pose difficulties to this process. Selection of adequate sub-molecular target epitopes determines accessibility for anchoring of drug conjugates and bulkier drug carriers, as well as proper signaling for uptake within the cell. Targeting design must adapt to physiological variables of blood flow, disease status, and tissue architecture by accommodating physicochemical parameters such as carrier composition, functionalization, geometry, and avidity. In many cases, opposite features need to meet a balance, e.g., sustained circulation versus efficient targeting, penetration through tissues versus uptake within cells, internalization within endocytic compartment to avoid efflux pumps versus accessibility to molecular targets within the cytosol, etc. Detailed characterization of these complex physiological factors and design parameters, along with a deep understanding of the mechanisms governing the interaction of targeted drugs and carriers with the biological environment, are necessary steps toward achieving efficient drug targeting systems. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:125 / 137
页数:13
相关论文
共 50 条
  • [21] Ligand-targeted therapeutics in anticancer therapy
    Theresa M. Allen
    Nature Reviews Cancer, 2002, 2 : 750 - 763
  • [22] Design of Nanodispersed Magnetoactive Systems for Targeted Drug Delivery
    Shaikhutdinova N.D.
    Shaikhutdinov T.F.
    Frolov G.A.
    Borisova A.I.
    Akopdzhanov A.G.
    Shtil A.A.
    Nanotechnologies in Russia, 2018, 13 (5-6): : 317 - 321
  • [23] Biomarker identification with ligand-targeted nucleoprotein assemblies
    Singer, Elizabeth M.
    Crocitto, Laura E.
    Choi, Yuri
    Loera, Sofia
    Weiss, Lawrence M.
    Imam, S. Ashraf
    Wilson, Timothy G.
    Smith, Steven S.
    NANOMEDICINE, 2011, 6 (04) : 659 - 668
  • [24] Ligand-targeted bacterial minicells: Futuristic nano-sized drug delivery system for the efficient and cost effective delivery of shRNA to cancer cells
    Jivrajani, Mehul
    Nivsarkar, Manish
    Nanomedicine-Nanotechnology Biology and Medicine, 2016, 12 (08) : 2485 - 2498
  • [25] Ligand-targeted theranostic nanomedicines against cancer
    Yao, Virginia J.
    D'Angelo, Sara
    Butler, Kimberly S.
    Theron, Christophe
    Smith, Tracey L.
    Marchio, Serena
    Gelovani, Juri G.
    Sidman, Richard L.
    Dobroff, Andrey S.
    Brinker, C. Jeffrey
    Bradbury, Andrew R. M.
    Arap, Wadih
    Pasqualini, Renata
    JOURNAL OF CONTROLLED RELEASE, 2016, 240 : 267 - 286
  • [26] Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle
    Schiffelers, RM
    Ansari, A
    Xu, J
    Zhou, Q
    Tang, QQ
    Storm, G
    Molema, G
    Lu, PY
    Scaria, PV
    Woodle, MC
    NUCLEIC ACIDS RESEARCH, 2004, 32 (19) : e149
  • [27] Review of recent preclinical and clinical research on ligand-targeted liposomes as delivery systems in triple negative breast cancer therapy
    Hajimolaali, Mohammad
    Dorkoosh, Farid Abedin
    Antimisiaris, Sophia G.
    JOURNAL OF LIPOSOME RESEARCH, 2024, 34 (04) : 671 - 696
  • [28] Development of ligand-targeted liposomes for cancer therapy
    Noble, CO
    Kirpotin, DB
    Hayes, ME
    Mamot, C
    Hong, K
    Park, JW
    Benz, CC
    Marks, JD
    Drummond, DC
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (04) : 335 - 353
  • [29] Effect of PEGylation on Ligand-Targeted Magnetoliposomes: A Missed Goal
    Estelrich, Joan
    Antonia Busquets, Maria
    del Carmen Moran, Maria
    ACS OMEGA, 2017, 2 (10): : 6544 - 6555
  • [30] Ligand-targeted liposomes directed against pathological vasculature
    Schiffelers, RM
    Molema, G
    ten Hagen, TLM
    Janssen, APCA
    Schraa, AJ
    Kok, RJ
    Koning, GA
    Storm, G
    JOURNAL OF LIPOSOME RESEARCH, 2002, 12 (1-2) : 129 - 135